Journal article icon

Journal article

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

Abstract:

Background: Available therapies for myelofibrosis may exacerbate cytopenias and are not indicated for patients with severe thrombocytopenia. The JAK2/FLT3 inhibitor pacritinib induced spleen responses with limited myelosuppression in phase 1/2 trials. We aimed to assess the efficacy and safety of pacritinib vs best available therapy in patients with myelofibrosis irrespective of baseline cytopenias.

Methods: In the international phase 3 PERSIST-1 trial, patients with higher-risk m...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1016/S2352-3026(17)30027-3

Authors


Vannucchi, AM More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, RDM, RDM Clinical Laboratory Sciences
Expand authors...
CTI BioPharma Corp More from this funder
Publisher:
Elsevier: Lancet Publisher's website
Journal:
Lancet Haematology Journal website
Volume:
4
Issue:
5
Pages:
e225-e236
Publication date:
2017-03-20
Acceptance date:
2017
DOI:
EISSN:
2352-3026
ISSN:
2352-3026
Pubs id:
pubs:689111
URN:
uri:6d22126f-0b16-47f8-a7b2-fda7a1781c22
UUID:
uuid:6d22126f-0b16-47f8-a7b2-fda7a1781c22
Local pid:
pubs:689111

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP